Catalog Products » CD40/TNFRSF5, His, Rat
Manual
Manual
COAs

CD40/TNFRSF5, His, Rat

CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells.
$300.00
Z04352-100

Ask us a question
Product Introduction
Species Rat
Protein Construction
CD40/TNFRSF5 (Val24-Arg193)
Accession # A6JXD6		 His
N-term C-term
Purity > 90% as determined by Bis-­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 20.39 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 28-38 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

CD40/TNFRSF5, His, Rat

The purity of CD40/TNFRSF5, His, Rat is greater than 95% as determined by SEC-HPLC. »

CD40/TNFRSF5, His, Rat

CD40/TNFRSF5, His, Rat on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells.
Synonyms CD40; CD40L receptor; TNFRSF5; CD40 antigen; CD40 molecule; CDw40; MGC9013;
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.